Adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 745-753

  Zhu, Zhi ^a   Ma, Shuai ^a   Zhao, Lei ^a   Sun, Zhe ^a   He, Anning ^a   Xu, Huimian ^a   Zheng, Xinyu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Drosophila melanogaster multisubstrate deoxyribonucleoside kinase; Oncolytic adenovirus; Safe control; Suicide gene therapy; Virus therapy

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; DEOXYRIBONUCLEOSIDE KINASE; GEMCITABINE; PHOSPHOTRANSFERASE; THYMIDINE KINASE 1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CATALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DROSOPHILA MELANOGASTER DEOXYRIBONUCLEOSIDE KINASE MUTANT GENE; EMBRYO; ENZYME ACTIVITY; ENZYME SPECIFICITY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; STOMACH CANCER; SUICIDE GENE THERAPY; VIRAL GENE THERAPY; VIRUS GENE; VIRUS MUTANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DROSOPHILA MELANOGASTER; FEMALE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTANT PROTEINS; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952021124     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.887     Document Type: Article

References (29)

1. Zheng X, Johansson M and Karlsson A: Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem 275: 39125-39129, 2000.
2. Zheng X, Johansson M and Karlsson A: Bystander effects of cancer cell lines transduced with the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster and synergistic enhancement by hydroxyurea. Mol Pharmacol 60: 262-266, 2001.
3. Zheng X, Johansson M and Karlsson A: Nucleoside analog cytotoxicity and bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol. Biochem Biophys Res Commun 289: 229-233, 2001.
4. Betham B, Shalhout S, Marquez VE and Bhagwat AS: Use of Drosophila deoxynucleoside kinase to study mechanism of toxicity and mutagenicity of deoxycytidine analogs in Escherichia coli. DNA Repair 9: 153-160, 2010.
5. Munch-Petersen B, Knecht W, Lenz C, Sondergaard L and Piskur J: Functional expression of a multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster and its C-terminal deletion mutants. J Biol Chem 275: 6673-6679, 2000.
6. Solaroli N, Bjerke M, Amiri MH, Johansson M and Karlsson A: Active site mutants of Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. Eur J Biochem 270: 2879-2884, 2003.
7. Solaroli N, Johansson M, Balzarini J and Karlsson A: Enhanced toxicity of purine nucleoside analogs in cells expressing Drosophila melanogaster nucleoside kinase mutants. Gene Ther 14: 86-92, 2007.
8. Mikkelsen NE, Munch-Petersen B and Eklund H: Structural studies of nucleoside analog and feedback inhibitor binding to Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. FEBS J 275: 2151-2160, 2008.
9. Chen MS and Prusoff WH: Association of thymidylate kinase activity with pyrimidine deoxyribonucleoside kinase induced by herpes simplex virus. J Biol Chem 253: 1325-1327, 1978.
10. Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W and Debatin KM: Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci USA 96: 8699-8704, 1999. (Pubitemid 29354854)
11. Wildner O and Morris JC: The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 60: 4167-4174, 2000. (Pubitemid 30636600)
12. Raki M, Hakkarainen T, Bauerschmitz GJ, et al: Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ther 14: 1380-1388, 2007. (Pubitemid 47423737)
13. Lambright ES, Amin K, Wiewrodt R, et al: Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther 8: 946-953, 2001. (Pubitemid 32600151)
14. Zhang ZL, Zou WG, Luo CX, et al: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13: 481-489, 2003. (Pubitemid 43231842)
15. Wang ZG, Zhao W, Ramachandra M and Seth P: An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation. Mol Cancer Ther 5: 367-373, 2006.
16. Ranki T, Sarkioja M, Hakkarainen T, von Smitten K, Kanerva A and Hemminki A: Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int J Cancer 121: 165-174, 2007. (Pubitemid 46753865)
17. Gan Y, Gu J, Cai X, Hu J, Liu XY and Zhao X: Adenovirus-mediated HCCS1 overexpression elicits a potent antitumor efficacy on human colorectal cancer and hepatoma cells both in vitro and in vivo. Cancer Gene Ther 15: 808-816, 2008.
18. Chen L, Chen D, Gong M, et al: Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells. Cancer Lett 284: 141-148, 2009.
19. Reid T, Galanis E, Abbruzzese J, et al: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62: 6070-6079, 2002. (Pubitemid 35244455)
20. Sandrini MP, Clausen AR, On SL, Aarestrup FM, Munch-Petersen B and Piskur J: Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner. J Antimicrob Chemother 60: 510-520, 2007. (Pubitemid 47299864)
21. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
22. Wierdl M and Potter PM: Update on gene therapy approaches for cancer. Curr Hematol Rep 4: 294-299, 2005.
23. Fillat C, Carrio M, Cascante A and Sangro B: Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 3: 13-26, 2003.
24. Johansson M, van Rompay AR, Degreve B, Balzarini J and Karlsson A: Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster. J Biol Chem 274: 23814-23819, 1999.
25. Johansson M, Brismar S and Karlsson A: Human deoxycytidine kinase is located in the cell nucleus. Proc Natl Acad Sci USA 94: 11941-11945, 1997. (Pubitemid 27467821)
26. Knecht W, Mikkelsen NE, Clausen AR, et al: Drosophila melanogaster deoxyribonucleoside kinase activates gemcitabine. Biochem Biophys Res Commun 382: 430-433, 2009.
27. Jordheim LP, Galmarini CM, Dumontet C: Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemother Pharmacol 58: 547-554, 2006. (Pubitemid 43999805)
28. Cappella P, Tomasoni D, Faretta M, et al: Cell cycle effects of gemcitabine. Int J Cancer 93: 401-408, 2001. (Pubitemid 32592060)
29. Morris JC, Wildner O: Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 1: 56-62, 2000.